HR Execs on the Move

Soda Health

www.sodahealth.com

 
Soda Health is a healthcare technology company focused on building solutions which eliminate health inequities and create a healthier America. Social Determinants of Health (SDOH) have a major impact on health and wellbeing, as well as the cost of care. Our mission is so important, we found a way to work SDOH into our company name.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Casey Bartolucci
Chief Commercial Officer Profile
Julie Fleischer
Senior Vice President of Marketing Profile

Similar Companies

Toyon Associates

Toyon Associates is a Concord, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enara Health

Enara Health is building a data-driven platform and network to scale obesity treatment. Based in San Mateo, Calif., and operating since March 2015, Enara Health offers unique hybrid digital and in-person weight loss programs based on precision medicine. By combining mobile technology with health care visits and providing patients with personalized physician-driven medical weight loss programs, Enara Health routinely helps patients lose—and keep off—more than 15% of their baseline weight, which is far greater than the results seen with other m-health interventions.

Family Service of Rhode Island

We are one of the oldest and largest non-profit human service agencies in Rhode Island. Our offices are located in Providence and North Kingstown, with children's residential treatment facilities in Smithfield, North Smithfield, Bristol, and East

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.